Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis by Lee, S.H. et al.
Estimation and partitioning of polygenic variation
captured by common SNPs for Alzheimer’s disease,
multiple sclerosis and endometriosis
S. Hong Lee1,2,∗, Denise Harold3, Dale R. Nyholt2, ANZGene Consortium{, International
Endogene Consortium{, the Genetic and Environmental Risk for Alzheimer’s disease (GERAD1)
Consortium{, Michael E. Goddard4, Krina T. Zondervan5, Julie Williams3, Grant W.
Montgomery2, Naomi R. Wray1,2,{ and Peter M. Visscher1,2,6,{
1The University of Queensland, Queensland Brain Institute, Brisbane, QLD 4072, Australia, 2Queensland Institute
of Medical Research, 300 Herston Road, Brisbane 4006, Australia, 3Medical Research Council (MRC) Centre for
Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine,
Cardiff University, Cardiff, UK, 4Department of Agriculture and Food Systems, University of Melbourne, Melbourne,
Australia, 5Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Oxford, UK
and 6The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia
Received May 31, 2012; Revised October 31, 2012; Accepted November 15, 2012
Common diseases such as endometriosis (ED), Alzheimer’s disease (AD) and multiple sclerosis (MS) account
for a significant proportion of the health care burden in many countries. Genome-wide association studies
(GWASs) for these diseases have identified a number of individual genetic variants contributing to the risk
of those diseases. However, the effect size for most variants is small and collectively the known variants ex-
plain only a small proportion of the estimated heritability. We used a linear mixed model to fit all single nu-
cleotide polymorphisms (SNPs) simultaneously, and estimated genetic variances on the liability scale using
SNPs from GWASs in unrelated individuals for these three diseases. For each of the three diseases, case and
control samples were not all genotyped in the same laboratory. We demonstrate that a careful analysis can
obtain robust estimates, but also that insufficient quality control (QC) of SNPs can lead to spurious results
and that too stringent QC is likely to remove real genetic signals. Our estimates show that common SNPs on
commercially available genotyping chips capture significant variation contributing to liability for all three dis-
eases. The estimated proportion of total variation tagged by all SNPs was 0.26 (SE 0.04) for ED, 0.24 (SE 0.03)
for AD and 0.30 (SE 0.03) for MS. Further, we partitioned the genetic variance explained into five categories by
a minor allele frequency (MAF), by chromosomes and gene annotation. We provide strong evidence that a
substantial proportion of variation in liability is explained by common SNPs, and thereby give insights
into the genetic architecture of the diseases.
INTRODUCTION
Common diseases including coronary heart disease, cancer,
mental disorders, chronic respiratory illnesses, inflammatory
bowel disease and diabetes account for the greatest health
care burden in many countries. Most of these common dis-
eases are complex and the risk of diseases are influenced by
multiple environmental and genetic factors. Identifying
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specific environmental risk factors and quantifying their con-
tributions to disease risk are difficult. In contrast, studies
show that genetic variation makes a substantial contribution
to disease risk for many common diseases (1,2) and genome-wide
association studies (GWASs) provide a powerful method to
identify genetic risk factors contributing to common diseases.
Many individual genetic variants contributing to disease risk
for a range of diseases have been identified using these
methods (3–5).
It is important to understand the genetic architecture of
complex diseases to help develop better methods for diagnosis
and treatment. The effect size for most variants is small and col-
lectively the known variants explain only a small proportion of
the estimated heritability for most diseases (3,6). This gap
between the estimated heritability and the proportion of variation
explained by known risk variants is generally referred to as ‘the
missing heritability’ (7,8). The estimates of the significance of
GWAS results must be corrected for the large number of tests
and as a consequence, GWAS analyses control false positives
at the expense of false negatives. Many other variants in
linkage disequilibrium with single nucleotide polymorphisms
(SNPs) on commercial genotyping chips could contribute to
disease risk, but have not been identified as genome-wide signifi-
cant. Yang et al. (2010) (9) demonstrated that approximately half
of the heritability (45% of the phenotypic variance) of human
height could be explained by considering all SNPs simultaneous-
ly in a linear model analysis. The results suggest that most of the
heritability is not missing, but has not been detected in current
GWAS data because the effect sizes for many variants are too
small. Moreover, much of the remaining ‘missing’ heritability
is likely to be due to incomplete linkage disequilibrium
between causal variants and SNPs on the early commercial
chips. Reduced linkage disequilibrium will occur if causal var-
iants have a minor allele frequency (MAF) different from (typic-
ally lower than) genotyped SNPs (10).
The methods derived for quantitative traits have been adapted
for case–control studies of disease using a linear mixed model,
in which the estimates made on the observed binary scale are
transformed to a scale of liability, whilst adjusting both for
scale and for ascertainment (11). Theory and pedigree simula-
tion suggest that the method is unbiased (11). We and others
have applied the methods to a range of diseases, including
schizophrenia (12), rheumatoid arthritis (13) and major depres-
sive disorders (14). Genetic variation is estimated when case–
case pairs and control–control pairs are, on average, more
similar genome-wide than case–control pairs. However, appli-
cation to binary traits has potential problems that do not arise for
quantitative traits. Quality control (QC) of SNP genotype data
and adjustment for possible population stratification are
important because any artefact that causes genotypes of cases
to be more similar to each other on average and controls to be
more similar to other controls would be estimated and inter-
preted as ‘genetic’ variance.
In this study, we have applied methods to estimate and par-
tition the proportion of variation attributable to causal variants
in linkage disequilibrium with common SNPs by analysing
data for endometriosis (ED), Alzheimer’s disease (AD) and
multiple sclerosis (MS); diseases associated with reproduction,
aging and the immune system. We recently conducted a
GWAS for ED using the same data as used here and reported
the proportion of variation in ED risk explained by common
SNPs (15). However, those estimates were not adjusted for as-
certainment and scale, nor were they further partitioned.
Importantly for this study, for all three diseases case and
control samples were not all genotyped in the same laboratory.
We demonstrate that a careful analysis can obtain robust esti-
mates, but also that insufficient QC of SNPs can lead to spuri-
ous results and too stringent QC is likely to remove real
genetic signals.
RESULTS
Estimated genetic variance tagged by all SNPs
After our standard QC protocol, the proportion of variation in
liability captured by all SNPs was estimated and ranged from
0.24 to 0.30 (Table 1). For ED, the estimated genetic variance
proportional to the total variance on the liability scale was 0.26
(SE 0.04). The estimates for the other diseases were similar
with the estimates on the liability scale of 0.24 (SE ¼ 0.03)
for AD and 0.30 (SE 0.03) for MS. The P-values for tests of
the estimates being different from zero for all three diseases
were highly significant (Table 1). The estimated genetic var-
iances on the liability scale using genome-wide SNPs were
lower than the heritability estimated from twin or family-
based studies, but much higher than variance explained by
genome-wide significant SNPs (Table 1). For AD, the propor-
tion of variance in liability explained by a GWAS is relatively
large (0.18) because of the very large effect of APOE
(16,17).
Data were also analyzed after a more stringent QC protocol.
There was a small decrease in the estimates of genetic vari-
ance and the P-values increased slightly (Supplementary Ma-
terial, Table S4). These small changes showed that the
estimates were robust and had stabilized given the QC proto-
cols implemented. We used the two-locus test (18) and
checked whether there were artefactual batch effects asso-
ciated with the case–control status (Supplementary Material,
Table 1. Estimated heritability using genome-wide SNP data after the stringent QC
Disease Case/control No. of SNPs h2l (SE)
a P-value Heritabilityb GWASc
ED 3154/6981 488 532 0.26 (0.04) 3.62e-11  0.5 (38) ,0.01 (15)
AD 3290/3849 499 757 0.24d (0.03) 2.15e-15  0.76 (40) 0.18d (16)
MS 1604/1953 293 474 0.30e (0.03) 7.15e-22 0.25–0.76 (46) 0.06e (23)
aEstimated genetic variance proportional to the total variance on the liability scale. bHeritability estimated from twin or family-based studies. cVariance explained
by genome-wide significant SNPs. dOf this, 0.04 can be attributed to the APOE locus. eOf this 0.03 can be attributed to the MHC region.











Figs S1–S3). The results show that stringent QC and control-
ling for possible batch effects in genotyping between cases and
controls made little difference to our estimates and there was
no apparent inflation caused by genotyping artefacts between
case and control samples across the three diseases (Supple-
mentary Material, Figs S1–S3).
Genetic variance partitioned by MAF
In order to explore whether common causal variants are respon-
sible for part of the variance explained by the SNPs, we under-
took an analysis partitioning the variance tagged by SNPs into
five components defined by MAF (Table 2). As expected, the
sum of the five components was similar to the single SNP set
analysis for each disorder. For ED, the estimated genetic
variances for five components ranged from 0.03 to 0.08
(SE ¼ 0.03–0.04) across the allele frequency range. The
highest estimates were for the categories of MAFs from 0.2 to
0.4. Approximately 90% of the estimated genetic variance
was explained by common SNPs of MAF . 0.1 (Table 2). For
AD, the pattern of the estimated genetic variance fluctuated
across the MAF categories, ranging from 0.0 for SNPs with
MAFs 0.1–0.2 up to 0.08 for SNPs with low MAFs (,0.1)
and MAFs between 0.3 and 0.4. A significant proportion of
the genetic variance was explained by common SNPs with
MAFs .0.2 (Table 2) (again reflecting APOE). Adjusting for
APOE by fitting five tagging SNPs in APOE as covariates
changed the partitioning results slightly (results not shown).
For MS, the estimated genetic variances for five components
ranged from 0.03 to 0.09 (SE ¼ 0.02–0.03), and the distribution
of the estimated genetic variance for MAF was similar to ED. A
substantial proportion of genetic variance (90%) was due to
common SNPs with MAFs .0.1.
Genetic variance partitioned by chromosome
We performed two kinds of analyses which estimated the pro-
portion of additive genetic variation contributed by individual
chromosomes: one in which the similarity relationship matrix
for each chromosome was fitted separately (one additive
genetic variance component per analysis) and one in which
we fitted 22 relationship matrices simultaneously (22 additive
genetic variance components). The estimates from the joint
analysis and those from each chromosomal analysis were
similar (Supplementary Material, Figs S4–S6), and only the
results from the joint analysis are presented in the main text
(Fig. 1). The sum of estimates from the joint analysis was
similar to the estimates from the analysis using all SNPs sim-
ultaneously in estimating relationships.
The estimates of variance explained by each chromosome
are linearly related to the length of the chromosome for ED
(R2 ¼ 0.59) (Fig. 1A) and for MS (R2 ¼ 0.37) (Fig. 1C).
However, for AD, there was no linear relationship between
the estimates and the length of the chromosome, although the
linear relationship became significant without the component
due to chromosome 19 (R2 ¼ 0.25) (Fig. 1B). These analyses
quantify the total amount of additive genetic variation tagged
by SNPs for each chromosome, and should be consistent with
reported GWAS findings on either the same or other datasets.
Accordingly, we observe a moderate deviation from the regres-
sion line for chromosome 7 for ED (Fig. 1A) and substantial
deviations for chromosome 6 for MS (Fig. 1C) and chromosome
19 for AD (Fig. 1B), consistent with the reported GWAS signals
at 7p, major histocompatibility complex (MHC) and APOE,
respectively. We estimated the contribution of the APOE
locus. We fitted the five most associated SNPs in the APOE
region from the Harold et al. analysis (listed in their Table 1:
rs2075650, rs157580, rs6859, rs8106922, rs405509) as covari-
ates and found that the variance explained by chromosome 19
dropped from 5 to 1%. These analyses demonstrate that the
APOE locus explains most of the variation for chromosome
19. We also used the weighted probit model (19) fitting the
five SNPs in the APOE region, and obtained 4% of the total
variance explained by the SNPs. For MS, we estimated the
variance attributed to the MHC region from 29799095 to
33162954 bp in chromosome 6. The estimated proportion of
variance in liability was 3% (Table 1).
Genetic variance partitioned based on SNP annotation
Partitioning the genetic variance explained by SNPs into two
components by creating relationship matrices from SNPs
located in genes and those not associated with annotated
genes (Table 3) showed that the variance explained by SNPs
associated with genes was equal to that explained by non-
genic SNPs for ED (Table 3). The variance associated with
annotated genes was greater than the proportion of the
genome that they represent for AD and MS, but this excess
variation was not significant (P ¼ 0.12 for AD and 0.06 for
MS). Further, we estimated the variance explained by specific
genes related to the diseases (12), i.e. CNS+ (20) for AD,
immune-related genes (21) for MS and genes annotated by
terms related to ED using Gene2MeSH (22) for ED (Supple-
mentary Material, Table S2). For MS, genetic variance was
Table 2. Estimated proportion of variance on the liability scales explained by all SNPs and partitioned by SNP MAF
MAF ED AD MS
No. of SNPs h2l (SE) No. of SNPs h
2
l (SE) No. of SNPs h
2
l (SE)
,0.1 83034 0.03 (0.03) 83002 0.08 (0.02) 40360 0.03 (0.02)
0.1–0.2 118571 0.03 (0.04) 121780 0.00 (0.03) 70550 0.08 (0.03)
0.2–0.3 102261 0.07 (0.04) 104937 0.06 (0.03) 63876 0.07 (0.03)
0.3–0.4 94183 0.08 (0.03) 96610 0.08 (0.03) 60243 0.09 (0.03)
0.4–0.5 90483 0.05 (0.03) 93428 0.02 (0.02) 58445 0.03 (0.02)
Total 488532 0.25 499757 0.25 293474 0.30











significantly enriched in immune-related genes (P ¼ 0.001)
(Supplementary Material, Table S2), consistent with the
results from validated genome-wide significant SNPs (23).
However, there was no enrichment of the CNS+ and
ED-related genes for AD and ED, respectively.
Control–control analyses
In extending the methods derived for quantitative traits to
binary traits, we cautioned that any artefacts causing geno-
types of cases to be more similar to each other on average,
Figure 1. Joint analysis for each chromosome for estimating the genetic variance using SNP data. (A) ED. y ¼ 20.0002 + 0.00009x, R2 ¼ 0.37, P ¼ 0.003. (B)
AD. y ¼ 0.0081 + 0.00003x, R2 ¼ 0.024, P ¼ 0.49 and omitting chromosome 19, y ¼ 0.00061 + 0.00007x, R2 ¼ 0.25, P ¼ 0.02. (C) MS. y ¼ 20.002509 +
0.00012x, R2 ¼ 0.31, P ¼ 0.007 and omitting chromosome 6, y ¼ 0.0014 + 0.0001x, R2 ¼ 0.45, P ¼ 0.0009.











and genotypes of controls to be more similar to other controls
would be estimated and interpreted as ‘genetic’ variance (11).
For all three case–control samples analysed here, cases
and controls were genotyped independently. To determine
whether artefacts could explain the case–control results, we
undertook analyses based on control–control comparisons,
with results presented in Supplementary Material, Table S3.
Under standard QC, five of the six control–control analyses
showed estimates of ‘genetic’ variance significantly different
from zero. After the most stringent QC, the estimates were
not significant, except for the 1958/QIMR and the Oxford
ED controls (OEC)/QIMR comparisons, where OEC are the
Oxford ED Controls, a sample that overlaps in part with the
1958 sample (therefore, the 1958/QIMR and OEC/QIMR esti-
mates are not independent). Although these results could
reflect genuine population differences, subtle differences in
genotyping and QC practices could generate differences in
allele frequencies for SNPs across the entire genome. One
known difference between the samples was that the genotypes
for the OEC, 1958 and AD samples were called from the raw
intensity data with the Illuminus (24) algorithm, whereas the
QIMR genotypes were called with the GenCall (25) algorithm.
The original intensity data were not available to us to allow
direct investigation of the impact of genotype calling algo-
rithm. However, the International Endogene consortium pro-
vided genotype data from a sample that partly overlapped
with the1958 sample, for which genotypes had been called
with the GenCall algorithm. To illustrate the problem more
clearly, we constructed three independent UK control datasets:
1958A (the subset of the 1958 cohort for which the same indi-
viduals were called with both Illuminus and GenCall), 1958B
(the subset of the 1958 cohort with genotypes called only with
Illuminus) and OECX (the OEC controls called with Illuminus
with any individuals featured in 1958A or 1958B removed).
Analyses under standard QC show that point estimates of
‘genetic’ variance for 1958A/1958B and 1958A/OECX with
1958A genotypes called by Illuminus are small and non-
significant, whereas the estimates when the 1958A genotypes
were called with the GenCall algorithm are large and for
1958A/OECX are significantly different from zero (Table 4).
The differences in genotype calling between the algorithms
for the 1958A cohort are subtle, with 99.697% (SD
0.2539%) of genotypes called the same. The distribution of
proportion of genotypes called the same over SNPs is given
in Fig. 2, with allele frequencies per SNP plotted in Supple-
mentary Material, Fig. S7. However, genotype calling algo-
rithm does not solely contribute to the control–control
results with the QIMR sample, since analyses of both
1958AI/QIMR and 1958AG/QIMR generates estimates of
‘genetic’ variance which are significantly different from
zero. In these examples, the estimates of genetic variance
become non-significant under the most stringent QC.
How do these control–control results impact on the inter-
pretation of the case–control results? When the most stringent
QC was applied to the case–control studies for ED, AD and
Table 4. Impact of genotype calling algorithm on estimates of heritability from
control–control samples
Disease Samples No. of SNPs h2o (SE) P-value
Standard QC
1958A (I)/1958B (I) 1076/1576 492893 0.00 (0.13) 1.00
1958A (G)/1958B (I) 1076/1576 492893 0.20 (0.14) 0.13
1958A (I)/OECX (I) 1076/2565 473047 0.04 (0.10) 0.66
1958A (G)/OECX (I) 1076/2565 466005 0.48 (0.10) 1.9e-06
1958A (I)/QIMR (G) 1076/1836 488150 0.53 (0.12) 4.7e-06
1958A (G)/QIMR (G) 1076/1836 472019 0.64 (0.12) 1.0e-07
Most stringent QC
1958A (G)/OECX (I) 1076/2565 313076 0.04 (0.10) 0.68
1958A (I)/QIMR (G) 1076/1836 397802 0.08 (0.12) 0.48
1958A (G)/QIMR (G) 1076/1836 337695 0.16 (0.12) 0.20
The 1958 cohort was split into a sample (1958A) for which genotypes had been
called with both Illuminus (I) and with GenCall (G) and into a sample only
called with Illuminus (1958B). The OECX sample is the OEC control samples
with 1958 cohort controls removed. In this way, 1958A, 1958B and OECX are
three independent control samples.
Figure 2. Histogram of the proportion of genotypes for each SNP that is called
the same for the 1958A cohort called by the Illuminus or GenCall algorithm.
Table 3. Estimated proportion of variance on the liability scales explained by
SNPs associated with annotated genes and SNPs not associated with annotated
genes
No. of SNPs Mb h2l (SE) h2l as % of total
ED
Genesa 253514 1370 (49%) 0.13 (0.03) 50%
Not in genes 235018 1408 (51%) 0.13 (0.03) 50%
Total 488532 2778 (100%) 0.27
AD
Genesa 259031 1367 (49%) 0.15 (0.03) 62%
Not in genes 240726 1412 (51%) 0.09 (0.03) 38%
Total 499757 2779 (100%) 0.24
MS
genesa 150499 1368 (49%) 0.19 (0.03) 62%
Not in genes 142975 1409 (51%) 0.11 (0.03) 38%
Total 293474 2777 (100%) 0.30
aSNPs were assigned to genes if they were positioned within 20kb from the
boundary of a gene. The P-value for difference between the proportion of
physical coverage and genetic variance of genic region is P ¼ 0.785, 0.117 and
0.059 and for ED, AD and MS, respectively.











MS, the estimates were reduced as expected (Supplementary
Material, Table S4), because the most stringent QC used
here is likely to exclude real genetic signals. Nevertheless, a
significant proportion of genetic variation was retained for
each dataset (60% of the estimates before this QC), and
the P-value for the estimates were still highly significant. Fur-
thermore, for AD and MS, the variance explained by SNPs in
genes is significantly more expected by chance (Table 3), a
result that is unlikely to be generated by genotyping artefacts.
The results from the ED sample should be considered with
more caution.
DISCUSSION
There has been considerable debate on the relative contribution
of common and rare variants to the risk of common diseases
(26,27). We have estimated genetic variances on the liability
scale using SNPs from GWASs in unrelated individuals for
three important diseases. Our estimates show that common
SNPs on commercially available genotyping chips capture sig-
nificant variation contributing to liability for all three diseases.
The estimated proportion of total variation tagged by all SNPs
was 0.26 (SE 0.04) for ED, 0.24 (SE 0.03) for AD and 0.30
(SE 0.03) for MS. These estimates are lower than those from
twin or family-based studies, but substantially higher for ED
and MS than the variance explained by genome-wide significant
SNPs for each disease. The comparison of additive variance
explained by all SNPs and the total genetic variation estimated
from twin and family-based studies is not straightforward.
However, the estimates from pedigree studies can be biased
by non-additive genetic variation and by confounding with en-
vironmental factors (28,29), whereas our estimates are based
on such distant relationships that such effect are expected to
be negligible.
To consider the allele spectrum for the contribution of
common variants to disease risk, we partitioned the variance
explained into five categories by MAFs. For each disease, a
substantial proportion of variation was explained by SNPs
with MAFs between 0.2 and 0.4. Linkage disequilibrium
between low frequency causal variants and common geno-
typed SNPs is low (30) and therefore, the observation that gen-
otyped SNPs with MAFs .0.2 explains a substantial
proportion of variation in liability points to underlying
common causal variants that are in high LD with these geno-
typed SNPs (12). Using simulation, Lee et al. (12) showed that
the estimated genetic variance for each MAF interval is likely
proportional to the real genetic variance in each MAF interval
(Supplementary Material, Table S6 in (12)), and those results
are applicable here also. One might hypothesize that the
reduced fertility and fecundity associated with both ED (31)
and MS (32), but not AD (which has age on onset after repro-
ductive years), could generate differences in the frequency dis-
tribution of risk alleles between the diseases. Our results
present no support for this hypothesis. However, the large
standard errors of the estimates of genetic variance associated
with the genome and with the allelic spectrum mean that it is
difficult to draw conclusions—much larger sample sizes and
ideally a better coverage of low frequency variants would be
needed to make stronger inference. In addition, the focus on
the allelic spectrum of risk variants for a particular disease
ignores the effect of those variants on other (unmeasured)
traits and therefore, the net effect of the risk variants on
fitness may be quite different from their apparent effects on
a single disease. Therefore, in principle our results could be
consistent with pleiotropy that is inevitable under a polygenic
architecture of multiple complex traits (33).
We estimated the variance explained by each chromosome
by a joint or separate analysis. When fitting one chromosome
at a time, the variance attributable to the chromosome could
include variance contributed by other chromosomes if there
is LD between chromosomes as a consequence of population
stratification (10,34). However, the inflation due to variance
contributed by other chromosomes was negligible, i.e. the esti-
mates from the joint and separate analyses were similar to
each other (Supplementary Material, Figs S4–S6), consistent
with the absence of population stratification (10).
There are now many case–control datasets available to
researchers for analysis. In a number of these, genotyping
was not performed on cases and controls in the same experi-
ment. For example, researchers increasingly rely on shared
controls from a repository or simply cannot afford to genotype
both cases and controls. These experimental designs can lead
to bias, for example due to technical artefacts or differences in
calling algorithms. Subtle artificial allele frequency differ-
ences between cases and controls will make the cases appear
to be more similar to each other than they are to the controls,
and this could cause the estimation of spurious genetic vari-
ance (11). Here, we show that with careful and stringent QC
steps, these potential problems can be overcome to a large
extent. However, we did find differences between control
cohorts (Table 4). Our results imply that differences in
calling algorithms can contribute to spurious estimation of
genetic variation. Therefore, caution should be applied when
estimating genetic (co)variation from samples that were geno-
typed separately and we advocate careful attention to ensure
that post-genotyping analysis procedures are the same across
cases and controls. This potential for bias is much less
severe for quantitative traits, because different cohorts are
likely to have samples across the entire range of phenotypes.
In conclusion, we estimated additive genetic variation that is
captured by the current generation of SNP arrays for three im-
portant diseases, and partitioned this variation according to
chromosome, MAF, gene and pathway groups. We provide
strong evidence that a substantial proportion of variation in li-
ability is explained by common SNPs, and thereby, give insights
into the genetic architecture of the diseases. Consistent with
reports on other diseases (11,13), schizophrenia (12,35) and
quantitative traits (9,10,36,37), these results point to a disease
model where the cumulative effect of many risk variants,
across a range of allele frequencies, together with environmental




ED is a gynaecological disease where tissue that resembles
endometrium is found growing on sites outside of the uterus,











and affects 6–10% of women of reproductive age (38). Symp-
toms vary, but typically include severe menstrual pain, chronic
pelvic pain, sub- or infertility and digestive system problems,
all of which can have major impacts on the overall health and
well-being of sufferers in addition to imposing significant
annual costs on health care systems (39). A GWAS was con-
ducted by the International Endogene Consortium with 2247
cases recruited at the Queensland Institute of Medical Research
and 924 cases recruited at the University of Oxford (15). All
cases had surgically confirmed disease and samples were geno-
typed on the Illumina Human670Quad BeadArray (15). Illu-
mina Human610Quad control genotypes for QIMR cases were
available for 1836 individuals in an adolescent twin study.
The Oxford controls were 5190 UK population controls
obtained from the Wellcome Trust Case Control Consortium
(WTCCC2). These controls were genotyped with the Illumina
Human1M-Duo array (15). The Wellcome Trust controls
consist of the 1958 British Birth Cohort and from the National
Blood Donors. Since the samples from the 1958 British Birth
Cohort were also used in the analysis of the Alzheimer’s
GWAS, but not with perfect overlap, we refer to the controls
used by the Oxford researchers as the OEC. For the ED analyses,
the QIMR and Oxford samples were combined. Genotypes from
Oxford cases and controls were called with the Illuminus (24)
algorithm. Genotypes from the QIMR cases and controls were
called with the GenCall (25) algorithm. Initial data for ED
were 3171 cases and 7026 controls with 496733 SNPs.
Alzheimer’s disease
The samples included 3333 cases and 1225 elderly screened
controls genotyped at the Sanger Institute on the Illumina
610-quad chip after filtering a stringent QC process for which
the details were described by Harold et al. (40). According to
Harold et al. (33), ‘these samples were recruited by the
Medical Research Council (MRC) Genetic Resource for AD
(Cardiff University; Institute of Psychiatry, London; Cambridge
University; Trinity College Dublin), the Alzheimer’s Research
Trust Collaboration (University of Nottingham; University of
Manchester; University of Southampton; University of
Bristol; Queen’s University Belfast; the Oxford Project to Inves-
tigate Memory and Ageing, Oxford University); Washington
University, St Louis, USA; MRC PRION Unit, University
College London; London and the South East Region AD
project (LASER-AD), University College London; Competence
Network of Dementia and Department of Psychiatry, University
of Bonn, Germany and the National Institute of Mental Health
AD Genetics Initiative’ (40). Population controls of 2699
samples from a WTCCC2 1958 cohort (Illumina 1.2M) were
additionally combined for analyses. Genotypes of cases and
controls were called with the Illuminus (24) algorithm (40).
Initial data for AD consisted of 3333 cases and 3924 controls
with 529 205 SNPs, which were quality controlled again.
Multiple sclerosis
There were 1618 cases from the Australia and New Zealand
(ANZ) cohort genotyped on the Illumina infinium
Hap370CNV array and 1988 healthy US controls of Caucasian
descent from Illumina iControlDB. According to the
ANZGene Consortium (41), ‘Australian MS cases were self-
identified volunteers recruited at centers located in Adelaide,
Brisbane, Gold Coast, Hobart, Melbourne, Newcastle, Perth
and Sydney. New Zealand MS cases were collected across
the country as part of a recent national prevalence survey.
Controls were provided by the Sanger Institute (Cambridge,
UK)’. These samples passed careful QC as previously
described (41) with genotypes called with the GenCall (25) al-
gorithm (41). Initial data for MS included 1618 cases and 1988
controls with 293 631 SNPs.
Quality control (QC)
Standard QC
Standard QC steps were applied to protect against artefacts
(11). SNPs with MAFs ,0.01, missing rates .0.05 or
P-value ,0.0001 for the Hardy–Weinberg equilibrium test
were excluded as were individuals with SNP missingness
rates .0.01. We also excluded subjects so that no pair of indi-
viduals had a similarity relationship coefficient .0.05
(equivalent to about second-cousins). Sex chromosomes
were excluded from the analysis. Supplementary Material,
Table S1 shows how many cases and controls, and SNPs
were excluded after the standard QC. After the standard QC
process, the number of samples and SNPs used for estimating
the genetic variance was 10135 individuals (3154 cases and
6981 controls) with 488532 SNPs for ED, 7139 individuals
(3290 cases and 3849 controls) with 499 757 SNPs for AD
and 3557 individuals (1604 cases and 1953 controls) with
293 474 SNPs for MS (Supplementary Material, Table S4).
Stringent QC
When two groups of samples are separately genotyped, batch
effects may influence the estimated genetic variances that are
systematically biased (11,18). Therefore, stringent QC was
applied to check how robust the estimates were. For this
test, SNPs for which P-values were ,0.05 for the Hardy–
Weinberg equilibrium and for missingness difference
between two groups were excluded. We also applied a two-
locus QC test (18) based on the difference in test statistic of
association between single SNPs and pairs of SNPs, and diag-
nosed whether there were artefact batch effects. After this
stringent QC, the number of SNPs was decreased although
the number of samples was not changed (Supplementary Ma-
terial, Table S1). The number of SNPs that remained was
416 816 SNPs for ED, 426 467 SNPs for AD and 261 309
SNPs for MS (Supplementary Material, Table S4).
Most stringent QC
In addition to the stringent QC, for some analyses we applied
even more stringent QC that is most likely to remove the true
signal as well as artefacts in the estimation of variance
explained by SNPs. In this most stringent QC, we compared
allele frequencies in each cohort with those from HapMap3
samples, and excluded SNPs having a significantly different
frequency from HapMap3 (P , 0.003). Subsequently, we
applied a two-locus QC step (18) to filter out problematic
SNPs. In the process of the two-locus QC, we excluded
SNPs that caused the joint two-SNP model to fit significantly
better (P , 0.02) than expected from the two single SNP
models (18), considering each of 20 flanking markers. In











addition, we fitted the first 50 principal components estimated
from the two control cohorts in the association model. The
number of SNPs that remained was 391 913 for ED, 403
398 for AD and 248 980 for MS (Supplementary Material,
Table S4).
Model
We estimated the variance in case–control status explained by
all SNPs using a linear mixed model,
y = Xb+ g + e (1)
where y is a vector of case (¼1) or control (¼0) status on the
observed scale, b is a vector for fixed effects of overall mean
(intercept), and 10 ancestry principal components (for ED,
cohort status, QIMR and Oxford, was additionally fitted as a
fixed effect to adjust for possible artefactual batch effects), g
is the vector of random additive genetic effects based on aggre-
gate SNP information and e is a vector of random error effects. X
is an incidence matrix for the fixed effects relating to indivi-
duals. The variance structure of phenotypic observations is
V = As2g + Is2e
Where s2g is the additive genetic variance tagged by the SNPs,
s2e is the error variance, A is the genomic similarity relationship
matrix estimated from SNP data and I is an identity matrix. The
genomic similarity relationship for each pair of individuals is
calculated as the sum of the products of SNP coefficients
between two individuals scaled by the SNP heterozygosity (9).
All variances are on the observed (0–1) scale, were esti-
mated using restricted maximum likelihood (42–44) and
were transformed to those on the liability scale as shown pre-
viously (11), assuming a disease prevalence (lifetime risk) of
8% for ED (15), 2% for AD (45) and 0.1% for MS (23).
Genome partitioning linear mixed model
We partitioned the variance explained by the SNPs in several
ways using the linear model
y = Xb+
∑n







where n is the number of subsets from any non-overlapping
partitioning of SNPs; n ¼ 22 for the joint analysis by chromo-
some and n ¼ 5 for the analysis by MAF bin. We partitioned
the variance by annotation n ¼ 2, when SNPs were annotated
as being in ‘genes’ or ‘not in genes’ where gene boundaries
were +20 kb from 3′ and 5′ UTRs of each gene. Further, we
annotated SNPs being in disorder-specific genes (Supplemen-
tary Material, Table S2). That is, SNPs were in genes if they
were positioned within 50 kb from the boundary of ED-related
genes (annotated by terms related to ED using Gene2MeSH
(22)), CNS+ (one set comprised genes expressed preferentially
in the brain compared with other tissues and the other three sets
comprised genes annotated to be involved in neuronal activity,
learning and synapses (20)) and immune-related genes (21)
for ED, AD and MS, respectively.
Control–control analyses
Since for each disorder, cases and controls were genotyped
separately, we were concerned that the estimated genetic vari-
ance could be biased due to artefacts, for example genotyping
batch effects or differential genotype calling algorithms. The
essential information on estimating genetic variation comes
from the average genomic similarity of case–case, case–
control and control–control groups, so any non-genetic effect
that makes cases more similar to other cases and controls
more similar to other controls will result in the estimated
genetic variance that is spurious. To explore the possibility of
artefacts, we applied a QC process that would control for most
artefact batch effects and performed pseudo case–control
studies on combinations of the control cohorts, by treating one
of the controls cohorts as ‘cases’. As several of the control
sets are overlapping, in order to clearly illustrate the impact of
QC factors confounded with cohort, we constructed three inde-
pendent UK control datasets: 1958A (the subset of the 1958
cohort for which the same individuals were called with both Illu-
minus, 1958AI, and GenCall, 1958AG), 1958BI (the subset of
the 1958 cohort with genotypes called only with Illuminus)
and OECXI (the OEC controls called with Illuminus with any
individuals featured in 1958A or 1958B removed.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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